NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Mylan N.V.  ("Mylan" or the "Company") (NASDAQ: MYL). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.

The investigation concerns whether Mylan and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934

On October 5, 2016, the Centers for Medicare and Medicaid Services ("CMS") published a report stating that for years Mylan had overcharged the U.S. Medicaid health program for its EpiPen shot, despite being to provide greater discounts under the law. The CMS letter stated that from 2011 to 2015, the U.S. Medicaid health program spent close to $797 million on EpiPens, including rebates of about 13%, instead of the 23.1% discount that the U.S. should have received.  The letter also said that the government has "expressly told Mylan that the [EpiPen] product is incorrectly classified." Following this news, Mylan stock dropped $1.19 per share, or 3.13%, to close at $36.84 on October 6, 2016.

If you are aware of any facts relating to this investigation, or if you purchased shares of Mylan, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/myl or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-mylan-nv-myl-300341013.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Copyright 2016 PR Newswire

Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Mylan NV Charts.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Mylan NV Charts.